Olga Vorontsova
Research Engineer at Department of Immunology, Genetics and Pathology; Research programme: Cancer Precision Medicine; Research group Bo Stenerlöw
- Telephone:
- +46 18 471 50 61
- Mobile phone:
- +46 70 425 05 61
- E-mail:
- olga.vorontsova@igp.uu.se
- Visiting address:
- Dag Hammarskjölds väg 20
751 85 Uppsala - Postal address:
- Rudbecklaboratoriet
751 85 UPPSALA
Publications
Recent publications
Part of International Journal of Molecular Sciences, 2023
- DOI for Feasibility of Co-Targeting HER3 and EpCAM Using Seribantumab and DARPin-Toxin Fusion in a Pancreatic Cancer Xenograft Model
- Download full text (pdf) of Feasibility of Co-Targeting HER3 and EpCAM Using Seribantumab and DARPin-Toxin Fusion in a Pancreatic Cancer Xenograft Model
Part of Pharmaceutics, 2022
- DOI for Experimental HER2-Targeted Therapy Using ADAPT6-ABD-mcDM1 in Mice Bearing SKOV3 Ovarian Cancer Xenografts: Efficacy and Selection of Companion Imaging Counterpart
- Download full text (pdf) of Experimental HER2-Targeted Therapy Using ADAPT6-ABD-mcDM1 in Mice Bearing SKOV3 Ovarian Cancer Xenografts: Efficacy and Selection of Companion Imaging Counterpart
Part of Journal of Nuclear Medicine, p. 1046-1051, 2022
Radionuclide therapy using ABD-fused ADAPT scaffold protein: Proof of Principle
Part of Biomaterials, 2021
- DOI for Radionuclide therapy using ABD-fused ADAPT scaffold protein: Proof of Principle
- Download full text (pdf) of Radionuclide therapy using ABD-fused ADAPT scaffold protein: Proof of Principle
Part of Pharmaceutics, 2021
- DOI for The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy Efficacy
- Download full text (pdf) of The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy Efficacy
All publications
Articles in journal
Part of International Journal of Molecular Sciences, 2023
- DOI for Feasibility of Co-Targeting HER3 and EpCAM Using Seribantumab and DARPin-Toxin Fusion in a Pancreatic Cancer Xenograft Model
- Download full text (pdf) of Feasibility of Co-Targeting HER3 and EpCAM Using Seribantumab and DARPin-Toxin Fusion in a Pancreatic Cancer Xenograft Model
Part of Pharmaceutics, 2022
- DOI for Experimental HER2-Targeted Therapy Using ADAPT6-ABD-mcDM1 in Mice Bearing SKOV3 Ovarian Cancer Xenografts: Efficacy and Selection of Companion Imaging Counterpart
- Download full text (pdf) of Experimental HER2-Targeted Therapy Using ADAPT6-ABD-mcDM1 in Mice Bearing SKOV3 Ovarian Cancer Xenografts: Efficacy and Selection of Companion Imaging Counterpart
Part of Journal of Nuclear Medicine, p. 1046-1051, 2022
Radionuclide therapy using ABD-fused ADAPT scaffold protein: Proof of Principle
Part of Biomaterials, 2021
- DOI for Radionuclide therapy using ABD-fused ADAPT scaffold protein: Proof of Principle
- Download full text (pdf) of Radionuclide therapy using ABD-fused ADAPT scaffold protein: Proof of Principle
Part of Pharmaceutics, 2021
- DOI for The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy Efficacy
- Download full text (pdf) of The Influence of Domain Permutations of an Albumin-Binding Domain-Fused HER2-Targeting Affibody-Based Drug Conjugate on Tumor Cell Proliferation and Therapy Efficacy
Part of Cancers, 2021
- DOI for Imaging-Guided Therapy Simultaneously Targeting HER2 and EpCAM with Trastuzumab and EpCAM-Directed Toxin Provides Additive Effect in Ovarian Cancer Model
- Download full text (pdf) of Imaging-Guided Therapy Simultaneously Targeting HER2 and EpCAM with Trastuzumab and EpCAM-Directed Toxin Provides Additive Effect in Ovarian Cancer Model
Part of Pharmaceutics, 2020
- DOI for Evaluating the Therapeutic Efficacy of Mono- and Bivalent Affibody-Based Fusion Proteins Targeting HER3 in a Pancreatic Cancer Xenograft Model.
- Download full text (pdf) of Evaluating the Therapeutic Efficacy of Mono- and Bivalent Affibody-Based Fusion Proteins Targeting HER3 in a Pancreatic Cancer Xenograft Model.
Part of Molecules, 2020
- DOI for Radionuclide Molecular Imaging of EpCAM Expression in Triple-Negative Breast Cancer Using the Scaffold Protein DARPin Ec1
- Download full text (pdf) of Radionuclide Molecular Imaging of EpCAM Expression in Triple-Negative Breast Cancer Using the Scaffold Protein DARPin Ec1